Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis: A 12-month follow-up study

E. Sotiriou, A. Lallas, C. Goussi, Z. Apalla, A. Trigoni, E. Chovarda, D. Ioannides

Research output: Contribution to journalArticle

Abstract

Background Actinic cheilitis (AC) may progress into fully developed squamous cell carcinoma with a relatively high risk of metastasizing and therefore requires early identification and treatment. Objectives To assess the clinical and histological long-term outcome as well as the safety and tolerability of sequential use of photodynamic therapy (PDT) and imiquimod in AC. Methods Patients with histologically confirmed grade 1 and 2 AC received two methyl aminolaevulinate-PDT sessions 2 weeks apart. After a 2-week rest period the patients started applying imiquimod 5% cream 3 days per week for 4 weeks. At the first follow-up visits at 3 and 6 months, noncomplete clinical responders were biopsied and excluded from the study if histological alterations were indicative for AC. At the last 12-month follow-up all remaining patients were biopsied. Adverse events were noted at weeks 2, 4, 6 and 8 of the treatment phase and at every visit of the follow-up period. Results Of the 34 enrolled patients, 30 completed the study. Complete clinical response was achieved by 27 patients in 3 months. At 6 months, clinical and histological recurrence occurred in two patients, while at 12 months the complete clinical cure rate obtained was 80% and the histological complete cure rate was 73%. Treatment was well tolerated and adverse events were as expected and transient. Conclusion Sequential use of PDT and imiquimod cream is of significant benefit for the treatment of AC. Further studies are needed in order to confirm the improved outcome using the combination treatment, to clarify the involved mechanisms and to optimize the therapeutic protocol.

Original languageEnglish
Pages (from-to)888-892
Number of pages5
JournalBritish Journal of Dermatology
Volume165
Issue number4
DOIs
Publication statusPublished - Oct 2011

Fingerprint

imiquimod
compound A 12
Photochemotherapy
Therapeutics
Actinic cheilitis
Squamous Cell Carcinoma
Safety
Recurrence

ASJC Scopus subject areas

  • Dermatology

Cite this

Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis : A 12-month follow-up study. / Sotiriou, E.; Lallas, A.; Goussi, C.; Apalla, Z.; Trigoni, A.; Chovarda, E.; Ioannides, D.

In: British Journal of Dermatology, Vol. 165, No. 4, 10.2011, p. 888-892.

Research output: Contribution to journalArticle

Sotiriou, E. ; Lallas, A. ; Goussi, C. ; Apalla, Z. ; Trigoni, A. ; Chovarda, E. ; Ioannides, D. / Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis : A 12-month follow-up study. In: British Journal of Dermatology. 2011 ; Vol. 165, No. 4. pp. 888-892.
@article{968238ed4bfe4139ad800e36e07c88e5,
title = "Sequential use of photodynamic therapy and imiquimod 5{\%} cream for the treatment of actinic cheilitis: A 12-month follow-up study",
abstract = "Background Actinic cheilitis (AC) may progress into fully developed squamous cell carcinoma with a relatively high risk of metastasizing and therefore requires early identification and treatment. Objectives To assess the clinical and histological long-term outcome as well as the safety and tolerability of sequential use of photodynamic therapy (PDT) and imiquimod in AC. Methods Patients with histologically confirmed grade 1 and 2 AC received two methyl aminolaevulinate-PDT sessions 2 weeks apart. After a 2-week rest period the patients started applying imiquimod 5{\%} cream 3 days per week for 4 weeks. At the first follow-up visits at 3 and 6 months, noncomplete clinical responders were biopsied and excluded from the study if histological alterations were indicative for AC. At the last 12-month follow-up all remaining patients were biopsied. Adverse events were noted at weeks 2, 4, 6 and 8 of the treatment phase and at every visit of the follow-up period. Results Of the 34 enrolled patients, 30 completed the study. Complete clinical response was achieved by 27 patients in 3 months. At 6 months, clinical and histological recurrence occurred in two patients, while at 12 months the complete clinical cure rate obtained was 80{\%} and the histological complete cure rate was 73{\%}. Treatment was well tolerated and adverse events were as expected and transient. Conclusion Sequential use of PDT and imiquimod cream is of significant benefit for the treatment of AC. Further studies are needed in order to confirm the improved outcome using the combination treatment, to clarify the involved mechanisms and to optimize the therapeutic protocol.",
author = "E. Sotiriou and A. Lallas and C. Goussi and Z. Apalla and A. Trigoni and E. Chovarda and D. Ioannides",
year = "2011",
month = "10",
doi = "10.1111/j.1365-2133.2011.10478.x",
language = "English",
volume = "165",
pages = "888--892",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis

T2 - A 12-month follow-up study

AU - Sotiriou, E.

AU - Lallas, A.

AU - Goussi, C.

AU - Apalla, Z.

AU - Trigoni, A.

AU - Chovarda, E.

AU - Ioannides, D.

PY - 2011/10

Y1 - 2011/10

N2 - Background Actinic cheilitis (AC) may progress into fully developed squamous cell carcinoma with a relatively high risk of metastasizing and therefore requires early identification and treatment. Objectives To assess the clinical and histological long-term outcome as well as the safety and tolerability of sequential use of photodynamic therapy (PDT) and imiquimod in AC. Methods Patients with histologically confirmed grade 1 and 2 AC received two methyl aminolaevulinate-PDT sessions 2 weeks apart. After a 2-week rest period the patients started applying imiquimod 5% cream 3 days per week for 4 weeks. At the first follow-up visits at 3 and 6 months, noncomplete clinical responders were biopsied and excluded from the study if histological alterations were indicative for AC. At the last 12-month follow-up all remaining patients were biopsied. Adverse events were noted at weeks 2, 4, 6 and 8 of the treatment phase and at every visit of the follow-up period. Results Of the 34 enrolled patients, 30 completed the study. Complete clinical response was achieved by 27 patients in 3 months. At 6 months, clinical and histological recurrence occurred in two patients, while at 12 months the complete clinical cure rate obtained was 80% and the histological complete cure rate was 73%. Treatment was well tolerated and adverse events were as expected and transient. Conclusion Sequential use of PDT and imiquimod cream is of significant benefit for the treatment of AC. Further studies are needed in order to confirm the improved outcome using the combination treatment, to clarify the involved mechanisms and to optimize the therapeutic protocol.

AB - Background Actinic cheilitis (AC) may progress into fully developed squamous cell carcinoma with a relatively high risk of metastasizing and therefore requires early identification and treatment. Objectives To assess the clinical and histological long-term outcome as well as the safety and tolerability of sequential use of photodynamic therapy (PDT) and imiquimod in AC. Methods Patients with histologically confirmed grade 1 and 2 AC received two methyl aminolaevulinate-PDT sessions 2 weeks apart. After a 2-week rest period the patients started applying imiquimod 5% cream 3 days per week for 4 weeks. At the first follow-up visits at 3 and 6 months, noncomplete clinical responders were biopsied and excluded from the study if histological alterations were indicative for AC. At the last 12-month follow-up all remaining patients were biopsied. Adverse events were noted at weeks 2, 4, 6 and 8 of the treatment phase and at every visit of the follow-up period. Results Of the 34 enrolled patients, 30 completed the study. Complete clinical response was achieved by 27 patients in 3 months. At 6 months, clinical and histological recurrence occurred in two patients, while at 12 months the complete clinical cure rate obtained was 80% and the histological complete cure rate was 73%. Treatment was well tolerated and adverse events were as expected and transient. Conclusion Sequential use of PDT and imiquimod cream is of significant benefit for the treatment of AC. Further studies are needed in order to confirm the improved outcome using the combination treatment, to clarify the involved mechanisms and to optimize the therapeutic protocol.

UR - http://www.scopus.com/inward/record.url?scp=80053571603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053571603&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2011.10478.x

DO - 10.1111/j.1365-2133.2011.10478.x

M3 - Article

C2 - 21916880

AN - SCOPUS:80053571603

VL - 165

SP - 888

EP - 892

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 4

ER -